To Study Prognosis Molecular Marker Of Prostate Cancer:P504S And B7-H3

Prostate cancer is the threat to the health of the common cancer of men. Although in our country, the incidence of prostate cancer is lower than the United States and Europe, but with our aging population gradually increased, the incidence of prostate cancer is also an increasing trend. The biological behavior of prostate cancer is Complex and diverse. Not only the potential need for treatment of cancer which no impact on patient survival, only the "healthy person with cancer", but clinical cancer whose cells can quickly transfer invasion, threatening the patient's life, need to do the effective, timely treatment. Therefore, understanding of the biological behavior of prostate cancer, can choose a treatment which could eventually transfer the cells targeted prostate cancer eventually transferred to the death and avoid unnecessary over-treatment of complications, and also can have the benefit of guiding significance for the patient's treatment which is rational and effective, explore the identification of sleep and aggressive prostate cancer, to determine the prognostic markers of prostate cancer is the current research focus of prostate cancer. The Types of prostate cancer is clinical cancer, latent cancer, and sporadic cancer. Latent cancer is also known as health cancer as this kind of prostate cancer don't have life-threatening, and will not affect the patients quality of life and does not require any treatment. While the real fatal prostate cancer accounts for only 3.6% of the total number, that is only 3.6% of patients with prostate cancer need to treat. Therefore, in the clinical treatment of prostate cancer, we first need to accurately identify which type of prostate cancer is. And then according to the other specific circumstances of patients develop effective individualized treatment plan. Can avoid unnecessary over-treatment, because over-treatment is not only a waste of human, material and financial resources, but also can cause serious consequences for patients, such as importence, premature ejaculation, sexual dysfunction, osteoporosis, etc. Although there are many studies about prostate cancer in the world, but is little understand about the prostate cancer prognostic molecular markers and countries in the study of race differences in access will inevitably lead to some results, while molecular markers of prostate cancer has a pivotal role in determining the biological characteristics prognosis and guiding treatment of prostate cancer. This study aimed to investigate whether the P504S and B7-H3 can be Molecular markers of China races to determine the prognosis of prostate cancer.Objective:To investigate the expression and clinical significances of P504S and B7-H3 protein in prostate carcinoma,and evaluate if it could be aprostate molecular marker in prostate cancer.Methods: 3rd Gen ImmunohistochemistryResults: (一)P504S The positive staining rates of P504S protein expression were 91.4% and 38.5% in patients with prostate cancer and benign prostate hyperplasia respectively.There was significant expres- sion(P<0.05);the positive staining rates of P504S protein expression were 85.0% and 94.0% in prostate cancer with different pathology stage (A-Cstage and D stage)respectively. There was no significant expression (P>0.05);The positive staining rates of P504S protein expression were 84.2% and 94.1% in prostate cancer with different pathology grade(Gleason scores≤7 and Gleason scores >7 )respectively. There was significant expression(P<0.05);The positive staining rates of P504S protein expres- sion were 76.5% and 96.2% in prostate cancer patients with different PSA value(PSA≤20 and PSA>20 )respectively, there was no significant expres- sion(P>0.05); The positive staining rates of P504S protein expression were 92.9% and 90.5% in prostate cancer with different endocrine therapy effect(good curative effect and bad curative effect),There was no significant expression(P>0.05); Log Rank test analysis showed that between the different positive (weakly positive, the positive, strong positive) the expression level of P504S in prostate cancer with negative expression of the survival time was no significant difference (p> 0.05); while between P504S negative and positive expression of the survival time was significant difference (p <0.05).(二) B7-H3 The positive staining rates of B7-H3 protein expression were 92.9% and 46.2% in patients with prostate cancer and benign prostate hyperplasia respectively.The B7-H3 expression was significantly higher in prostate cancer than that in benign prostate hyperplasia (P<0.05);The positive staining rates of B7-H3 protein expression were 90% and 94% in prostate cancer with different patho- logy stage (A-Cstage and D stage)respectively. The B7-H3 expression was significantly higher in D stage prostate cancer than that in A-C stage prostate cancer. (P<0.05);The positive staining rates of B7-H3 protein expression were 84.5% and 94.1% in prostate cancer with different pathology grade(Gleason scores≤7 and Gleason scores >7 )respectively. There was no significant expression(P>0.05);The positive staining rates of B7-H3 protein expression were 82.4% and 96.2% in prostate cancer patients with different PSA value(PSA≤20 and PSA>20 )respectively, there was no significant expression(P>0.05); The positive staining rates of B7-H3 protein expression were 89.2% and 95.2% in prostate cancer with different endocrine therapy effect(good curative effect and bad curative effect),There was significant expression(P<0.05); Log Rank test analysis showed that between the different positive (weakly positive, the positive, strong positive) the expression level of B7-H3 in prostate cancer with negative expression of the survival time was no significant difference (p> 0.05); while between B7-H3 negative and positive expression of the survival time was significant difference (p <0.05).